Emerging Biotechnology Organization Awards $1.3 Million Study Extension to eResearchTechnology for Cardiac Safety Monitoring and

Emerging Biotechnology Organization Awards $1.3 Million Study
Extension to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Overall Agreement Now Totals More than $4.2 Million, and Includes Thorough ECG
Study Profile 


PHILADELPHIA, May 6  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
, a leading provider of centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received an agreement for
about $1.3 million in additional cardiac safety monitoring and services from an
emerging biotechnology organization for one of its drug candidates in clinical
development.  The additional award brings to more than $4.2 million the total
services contracted to eRT for this single clinical trial.

The agreement covers an extension to a significant Phase III study for which
eRT was already providing comprehensive support, including the provision,
training and ongoing assistance required for effective use of digital 12-lead
Holter equipment designed to facilitate 24-hour digital recording of cardiac
safety data that is subsequently provided to eRT for analysis.  The extension
will enable collection and analysis of additional cardiac safety data that will
be critical in determining the definitive cardiac effects of this new drug
candidate.  eRT will perform digital collection, measurement, interpretation,
review, and distribution of cardiac safety data through its EXPeRT workflow
enabled data handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory guidance and
technical standards.  The study extension is targeted for completion over a
90-day period.

"eRT's continuous 12-lead ECG recording platform has proven invaluable to this
sponsor's desire to further enhance the cardiac safety data being collected and
analyzed for this important compound," said Scott Grisanti, senior vice
president of business development and chief marketing officer at eRT.  "This
extension further demonstrates the importance of safety profiling in later
stage development and illustrates that eRT's scalable capacity is key to the
ability to rapidly deliver on unplanned increases in study demands."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The sponsor may cancel this agreement at its sole discretion.  As a
result, actual results may differ materially from any financial outlooks stated
herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology,

Inc.



Web site:  http://www.ert.com/ 

Copyright